Menarini asked Origin to develop a global brand name (excluding North America and Japan) for Delafloxacin – a novel anionic Fluoroquinolone primarily indicated for the treatment of acute bacterial and skin structure infections
Delafloxacin is a next-generation broad spectrum fluoroquinolone and offers physicians the flexibility of fixed dose intravenous and/or oral dosage formulations and provides a new therapeutic option
Coined from ‘quinolone’, ‘defend’ and ‘next-generation’; Quofenix is powerful and dynamic sounding with an innovative/scientific tone. Quofenix re-enforces the key messages of superior efficacy, broad-control and first-line treatment.